Navigation Links
Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
Date:9/10/2008

evious pre-mixed insulins. At baseline, the characteristics of participants (49% female) were (mean plus or minus SD): age, 61 plus or minus 8 years; BMI, 30.1 plus or minus 3.7 kg/msquared; diabetes duration, 13 plus or minus 6 years; and insulin use, 5 plus or minus 4 years.

Additional study findings showed that LANTUS(R)/APIDRA(R) therapy provided significantly better mean daytime BG (p=0.0033) and PPBG (p<0.0001) versus pre-mixed insulins (baseline/endpoint daytime BG in mmol/L were 10.2/7.6 and 10.5/8.2 for LANTUS(R)/APIDRA(R) and pre-mixed insulins respectively. Baseline/endpoint PPBG in mmol/L were 10.9/7.8 and 11.4/8.9 for LANTUS(R)/APIDRA(R) and pre-mixed insulins respectively. FBG showed a tendency for a more pronounced decrease with the LANTUS(R)/APIDRA(R) treatment therapy versus pre-mixed insulin (p=0.0684) Baseline/endpoint FBG in mmol/L were 9.8/7.4 and 9.7/8 for LANTUS(R)/APIDRA(R) and pre-mixed insulins respectively .Compared with patients on pre-mixed insulin, patients were treated with higher mean daily insulin doses at endpoint with the LANTUS(R)/APIDRA(R) treatment therapy (98.0 plus or minus 48.7 versus 91.3 plus or minus 44.3 U; p=0.0003) and showed slightly greater weight gain (+3.6 plus or minus 4.0 kg versus +2.2 plus or minus 4.5 kg; p=0.0073).

About the LACE Study

Patients with type 2 diabetes at two U.S. endocrinology practice centers were randomized to LANTUS(R) and APIDRA(R) (n=106) or analog pre-mixed insulin (n=91). Subsequent to randomization, patients continued treatment following each center's usual practice with no additional therapeutic protocols. Data collected with variations at 0, 3, 6 and 9 months included A1C, hypoglycemia, insulin dose, concomitant medications, and therapy change. Medication costs were estimated using published average wholesale price. Time variations between visits were accounted for in the analysis of A1C.

Treatment groups were comparable at baseline with mean age 56 years, 46
'/>"/>

SOURCE Sanofi Aventis
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
2. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
5. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. New Resource Available for People With Lymphoma
8. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
9. LAP-BAND(R) System Weight-Loss Surgery Associated With More Than 70 Percent Reduced Risk of Death in People With Severe Obesity
10. Treating Depression Prolongs Life for Older People with Diabetes
11. People With Diabetes May Have All-Natural Citrus Supplement To Help Lower Blood Glucose and Cholesterol Levels
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... Omeros Corporation (NASDAQ: OMER ), ... commercializing both small-molecule and protein therapeutics for large-market ... and disorders of the central nervous system, today ... quarter 2015 financial results for the period ended ... after market close. Omeros management will host a ...
(Date:5/5/2015)... 2015  InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; ... specializes in developing safer, more effective cannabis-based therapies, ... and Non-Executive Director, Peter Mountford , has ... primary responsibility for the European markets. ... his previous success in the emerging field of ...
(Date:5/4/2015)... and VANCOUVER, British Columbia ... OGXI ) announced today that it will report ... 14, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015 2InMed Engages Peter Mountford as Strategic Advisor 2InMed Engages Peter Mountford as Strategic Advisor 3InMed Engages Peter Mountford as Strategic Advisor 4
... CS, a cancer survivorship case management software program jointly ... ) and Equicare Health, Inc., has been included by ... in its "Best Practices Repository." The repository is a ... in the U.S. adopt rigorous standards for high-quality patient-centered ...
... May 29, 2012  Echo Therapeutics, Inc. (Nasdaq: ... Symphony® tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced that ... Echo Therapeutics will present at the Jefferies 2012 ...
Cached Medicine Technology:EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC) 2EQUICARE CS Cancer Survivorship Case Management Software Listed as a "Best Practices" Resource by the American College of Surgeons Commission on Cancer (COC) 3Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 2Echo Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference 3
(Date:5/5/2015)... 2015 NovaSom, Inc., announced today that ... Innovations with Ed Begley Jr., airing via Discovery Channel ... This segment will focus on NovaSom, a leader in ... about their AccuSom® home sleep test, which is the ... patient support and next-day test results and interpretation. ...
(Date:5/5/2015)... MO (PRWEB) May 05, 2015 After ... bar flavors in 2014, Walgreens introduces the Cookies & ... focusing on innovation, Extend Nutrition has continually raised the ... a great taste, combined with an unprecedented nutritional profile, ... on this success, Extend Nutrition will launch additional new ...
(Date:5/5/2015)... After conducting a nationwide executive search ... West Holt Medical Services in Atkinson, Neb., ... skilled healthcare executive with more than 10 years of ... June 1st. , “Brad brings a proven track record ... and success in building strong relationships with physicians,” said ...
(Date:5/5/2015)... Saint Louis, MO (PRWEB) May 05, 2015 ... May 12, 2015 from 5:00 to 8:00 pm at the ... than 50 hospitals, clinics and groups with career opportunities will ... represented. Attendees will enjoy free hors d’oeuvres and raffle prize ... PracticeMatch says, “Rochester is an ideal location to hold ...
(Date:5/5/2015)... Cincinnati, OH (PRWEB) May 05, 2015 ... healthcare ministry serving Ohio and Kentucky – has devoted ... Be Well videos to childhood obesity issues. Experts say ... In a concise video on Mercy Health’s YouTube channel, ... ,     Why is childhood obesity worse now ...
Breaking Medicine News(10 mins):Health News:Innovations with Ed Begley, Jr. to Explore NovaSom, Inc., in Upcoming Episode 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:West Holt Medical Services Hires New Chief Executive Officer 2Health News:West Holt Medical Services Hires New Chief Executive Officer 3Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 2Health News:PracticeMatch to Host Physician Career Fair at the Rochester Marriott on May 12, 2015 3Health News:Videos provide helpful information about childhood obesity 2
... Financing Provides Capital to Complete EVEREST Pivotal Study and Begin ... European Commercialization ... Investors, MENLO PARK, Calif., Dec. 4 Evalve, Inc., the leader ... that it had successfully completed a $60 million Series D,financing. BBT Fund ...
... Bivalirudin lowers bleeding risk for patients undergoing bypass, study ... newer kind of anticlotting drug is safe over the ... heart attacks. , The drug, a "direct thrombin inhibitor" ... during cardiac procedures such as bypass surgery. , "We ...
... some truth to the popular wisdom that plump babies are ... people who had a low birth weight are more likely ... found that even people who had just mild or moderate ... smaller babies than those who had better mental health, said ...
... of New Orleans residents in months after the disaster, study ... the people living in New Orleans and about one-quarter of ... signs of a mood or anxiety disorder five to seven ... Researchers surveyed 1,043 residents in Louisiana, Alabama and Mississippi. , ...
... TARRYTOWN, N.Y., Dec. 4 EpiCept Corporation,(Nasdaq and OMX ... offering of 3,333,333 million shares of its common stock ... to approximately 1,666,667,million shares of common stock at an ... $4.7 million in net proceeds from the,offering. Rodman & ...
... Nabi,Biopharmaceuticals (Nasdaq: NABI ) announced ... assets constituting its Biologics strategic business unit ... of Biotest,AG, for $185 million in cash. ... has acquired or will acquire the Biologics ...
Cached Medicine News:Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 2Health News:UPDATED: Evalve(R) Completes $60 Million Series D Financing 3Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 2Health News:Newer Anticlotting Drug Safe, Effective for Heart Surgeries 3Health News:Smaller babies more prone to depression, anxiety later on 2Health News:Many Katrina Survivors Suffered Psychological Symptoms 2Health News:EpiCept Corporation Announces Pricing of Public Offering 2Health News:EpiCept Corporation Announces Pricing of Public Offering 3Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 2Health News:Nabi Biopharmaceuticals Completes Sale of Nabi Biologics to Biotest AG 3
... image guided surgery system offers full-featured ... design and use. It provides unparalleled ... localize critical anatomy and plan optimal ... surgeons an easy-to-use, technologically advanced approach ...
Assists in early recognition of changes in the macula and foveal areas., ,Only 6 patient responses required for diagnosis of functional disturbances, from small scotoma to distortions. Full instructi...
... Clips have become a required ... ,These useful and inexpensive clips ... patient's spectacle frame. Each cell ... and the rubber coating on ...
Designed for young and disabled children but equally suitable for older children and adults., ,Optional 6/60 to 6/24 booklet available for patients who fail standard screening test and require fu...
Medicine Products: